Viral drug resistance and fitness. (Q37034618)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086415%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

Viral drug resistance and fitness (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086415%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

main subject

viral drug resistance

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086415%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Miguel E Quiñones-Mateu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086415%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Dawn M Moore-Dudley

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086415%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Oyebisi Jegede

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086415%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Eric J Arts

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086415%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

language of work or name

1 reference

1 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086415%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

published in

Advances in Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086415%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086415%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

257-296

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086415%20AND%20SRC:MED&resulttype=core&format=json

Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Is HIV-1 evolving to a less virulent form in humans?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Susceptibility of HIV type 1 to the fusion inhibitor T-20 is reduced on insertion of host intercellular adhesion molecule 1 in the virus membrane

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Core structure of gp41 from the HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinase-dependent signaling pathway and enhances human immunodeficiency virus type 1 infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

HIV drug resistance and viral fitness.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Resistance to newly approved and investigational protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Structure of a V3-containing HIV-1 gp120 core

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Implications of antiretroviral resistance on viral fitness

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Fitness of drug resistant HIV-1: methodology and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Virus fitness: concept, quantification, and application to HIV population dynamics.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

1 reference

7 January 2021

Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Stable rearrangements of the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Structural analysis of reverse transcriptase mutations at codon 215 explains the predominance of T215Y over T215F in HIV-1 variants selected under antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2956009-6

7 January 2021

10.1016/S1054-3589(07)56009-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18086415%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference